ESLA
ESLA
NASDAQ · Biotechnology

Estrella Immunopharma Inc

$1.06
+0.00 (+0.00%)
As of Apr 1, 3:26 PM ET ·
Financial Highlights (FY 2025)
Revenue
18.42M
Net Income
959.9K
Gross Margin
61.9%
Profit Margin
5.2%
Rev Growth
+1.0%
D/E Ratio
0.15
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 61.9% 61.9% 61.9%
Operating Margin 6.9% 7.6% 7.7%
Profit Margin 5.2% 6.0% 6.1%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 18.42M 17.19M 14.45M
Gross Profit 11.41M 10.65M 8.95M
Operating Income 1.26M 1.30M 1.12M
Net Income 959.9K 1.03M 875.1K
Gross Margin 61.9% 61.9% 61.9%
Operating Margin 6.9% 7.6% 7.7%
Profit Margin 5.2% 6.0% 6.1%
Rev Growth +1.0% +13.6% +14.7%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 5.50M 6.16M 6.85M
Total Equity 35.90M 38.17M 33.17M
D/E Ratio 0.15 0.16 0.21
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 1.74M 1.49M 1.43M
Free Cash Flow 993.5K 1.08M 606.8K